Cutting Edge Technology to Improve Ancient Medicines

Want to speak to a representative?

We are here to help. Get in touch with us to speak with one of our specialists.

Schedule Appointment

About Us

Apollon Formularies is a London, England and Jamaican based publicly traded (AQUS:APOL), international medical cannabis pharmaceutical company specialising in cutting edge research and treatment of patients with cancer and chronic pain. Apollon is federally legal, licensed by the Cannabis Licensing Authority (CLA) in Jamaica, holds a suite of CLA licences which allow the company to work with full spectrum oils inclusive of high levels of THC. Apollon medical cannabis formulations are currently available by prescription to any licensed Jamaican doctor for their patients and for export via licensed partners to any jurisdiction allowing legal import.

Our strategy

To become the premier global medical cannabis company legally licensed to develop successful personalised clinical treatment utilizing artificial intelligence on clinical trial patient data.

Apollon’s Research & Development Licence allows drug discovery using THC and other cannabinoids. This allows Apollon to be the rare European listed company conducting medically supervised trials using THC to develop new therapeutics.

Our Goals

It aims to create a globally recognised brand synonymous with quality, consistent potency, and successful patient outcomes on a range of products for a variety of conditions within the medical cannabis space.

Apollon Formularies will, through its subsidiary Apollon Formularies Jamaica Ltd (a fully licensed full spectrum medical cannabis company), develop, market, distribute and sell full spectrum (inclusive of THC) products in the legal hemp and medical cannabis industry. It is currently producing pharmaceutical, nutraceutical and other medical cannabis related products. Apollon Formularies was established to advance the current significant commercial opportunities in the legal medical cannabis markets globally.

Our Licenses

Apollon Formularies Jamaica Limited (“Apollon Jamaica”) is licensed to operate at the Federal level in Jamaica and hold the following licences and approvals:

  • Research and Development Licence (Experimental)
  • Retail Licence (Therapeutic)
  • Processing Licence
  • Cultivation (R&D)
  • Export (Based on the above licences)

Together these licences create a vertically integrated full spectrum (inclusive of THC) medical cannabis company both in Jamaica and to the international market via legal export from Jamaica to jurisdictions where the law allows import of medical cannabis products.

Use of artificial intelligence

Apollon uses the latest state-of-the-art artificial intelligence techniques to optimize strain genetics for medical cannabis formulation development and to analyse patient genomic data to identify new potential biomarkers to triage patients into the correct treatment protocols.

Processing & extraction

Apollon’s CLA licensed Processing Laboratory is based in Negril, Jamaica. This state-of-the-art medical cannabis processing facility produces medical quality full spectrum medical cannabis oil (inclusive of THC). Apollon recently won the prestigious Jack Herer Cup 1st Place for Best Oil (solvent) which was produced in our Negril laboratory.

Medically supervised treatments

The company is currently opening the Apollon International Cancer Institute in Kingston, Jamaica to add to our patient treatment and clinical trial capacity currently in Negril, Jamaica.

Apollon has a full team of licensed Jamaican medical doctors specialising in oncology, palliative care, chronic pain, neurosurgery, surgery and general wellness with additional expertise in treating patients with Apollon medical cannabis products which are available in Jamaica by prescription only.

Apollon’s Timeline of Global Accomplishments

  1. Apollon Formularies created by Dr. Stephen Barnhill and his family in order to help cancer patients globally with medical cannabis as it helped his mother who suffered with pancreatic cancer.
  2. Completes Artificial Intelligence (AI) analysis for best strains to treat cancer and other conditions.
  3. Invited to present artificial intelligence cannabis strain results at the medical school at The University of the West Indies.
  4. Expands operations to Jamaica.
  5. Wins 1st place at the Jamaican International HighTimes Cannabis Cup for best Indica strain used to treat cancer patients.
  6. Signs Memorandum of Understanding (MOU) with the University of the West Indies to perform fundamental, academic and medical patient research and allowed production and sales of medical cannabis for cancer patients.
  7. Apollon Negril Facility opens for cancer patients using Apollon medical cannabis.
  8. Apollon Receives Cannabis Licence Authority (CLA) Conditional Approval for cultivation, processing, research and development for manufacturing medical cannabis products and treating cancer patients.
  9. Approved by CLA for full licence for Research and Development (Experimental).
  10. Approved by CLA for full licences for Retail (Theraputic) and Processing (Tier 2).
  11. Establishes Pharmaceutical Processing Labratory.
  12. Wins prestigious Jack Herer Cup 1st place for best medical cannabis oil (solvent). Same Apollon oil used to treat cancer patients.
  13. Apollon Negril Facility wins 1st in the world for medical cannabis health and wellness resort selected by Edibles magazine.
  14. Apollon medical proprietary cannabis treatment formulations tested by 3rd party independent laboratory testing at BIOENSIS with results expected in early 2021.
  15. Expands to Europe and becomes one of the first publicly listed medical cannabis companies on the Aquis exchange in London licenced to have high THC prescription medical products (AQUS:APOL).
  16. Joint testing by BIOENSIS has revealed combined formulations with Aion Therapeutics Inc. are effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers.
  17. Opens the Apollon International Cancer Institute for Complementary and Alternative Medicine (CAM), in Jamaica with medical cannabis treatments available by physician prescription.
  18. Apollon’s medical cannabis formulations were shown to be effective in killing both hormone-resistant and hormone-sensitive prostate cancer cells in 3D cell cultures in third party independent laboratory testing by BIOENSIS.

Expertise

From seed to patient

Apollon Cultivation

Cultivation

Apollon won Jamaican International High Times Cannabis Cup 1st Place for Best Indica Flower

Apollon won prestigious Jack Herer Cup 1st Place for Best Oil (Solvent)

Processing and Extraction

Apollon won prestigious Jack Herer Cup 1st Place for Best Oil (Solvent) at CanEx, Jamaica

Medically Supervised Treatments

International Cancer Institute

Apollon opens first International Cancer Institute in Kingston, Jamaica for Complementary and Alternative Medicine (CAM) prescribing Apollon products

Medically Supervised Treatments

Apollon Negril Facility

This facility has been utilised since 2015 to provide in-patient and out-patient medical cannabis treatment for use by patients needing access to prescribed medical cannabis. Apollon has treated in excess of 400 patients in the last 24 months at this facility.

Apollon Vape Pen

Retail Product Sales

Apollon won 1st Place for Best Indica Vape, Best Tincture and Best whole plant CBD VAPE From Edibles Magazine

Apollon’s CLA Research and Development Labratory

Research & Development

Apollon’s CLA Research and Development Licence allows for medical cannabis clinical trials under the direction of the Ministry of Health (MOH)

Apollon developing a 3D printer

Bespoke Treatments and Products

Apollon is developing a 3D printer to allow high quality medical cannabis pharmaceuticals with consistent dosing internationally with licensed partners

Schedule Appointment

Schedule an appointment with us to discuss either:
Physician Consultation, Share Dealing Enquiries, General Enquiries or legal wholesale purchase of Apollon Products

Trademarked Products

Apollon has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

APOLLON FULL EXTRACT CANNABIS OIL (FECO) Vape

Vape Pen

APOLLON THC Vape

The Apollon CBD Cartridge is a 500mg glass and stainless steel cartridge filled with wonderfully potent single origin, full plant, solvent free cannabis extract with the native terpenes reintroduced in post processing. There’s also zero pesticide or fungicide.

The strain used was “Ringo’s Gift”. Ringo’s Gift is a high-CBD strain that crosses Harle-Tsu and ACDC, named for the late Lawrence Ringo, a cannabis activist. When they say it’s high in CBD, they mean it: 70% CBD and 5% THC, that’s a 14:1 ratio and on top of that RG has a terpene profile of 11%. The moment you vape it you can feel the pain and anxiety begin to be relieved. The taste is delicious too and you can definitely detect the terps as you exhale.

Independant review by Edibles Magazine

APOLLON FECO Oral Tincture

30ml Bottle

APOLLON CBD & THC Oral Spray

The 30ml pump-action bottle of Oral Spray contains 750mg of CBD in addition to THC, CBG, and CBC – each are powerful cannabinoids on their own but working together in the following formulation they operate on a level of healing and maintenance you’ll need to experience to believe. Each is listed below along with some of their greatest individual benefits.

THC – Tetrahydrocannabinol 57mg. THC provides pain relief, eases nausea and vomiting, protects brain cells, aids with sleep. helps treat PTSD, increases appetite, is anti-inflammatory, and relaxes muscles.

CBD – Cannabidiol 750mg. CBD benefits include acting as an anti-inflammatory, anticonvulsant, antioxidant, antiemetic, anxiolytic and antipsychotic agent.

CBG – Cannabigerol 11mg. CBG reduces intraocular pressure, and is an effective antibacterial agent.

CBC – Cannabichromene 10mg. Blocks pain and inflammation, and inhibits the uptake of anandamide, allowing other cannabinoids to remain longer in the bloodstream.

Independant review by Edibles Magazine

APOLLON FECO Capsules

Perscribed Capsules

APOLLON 12:1:1 CBD Capsules

This bottle contained 10 capsules that were each 33mg so you have 330mg total. The cannabis used is Ringo’s Gift, a high-CBD strain that crosses Harle-Tsu and ACDC. It is named for the late Lawrence Ringo, a cannabis activist and CBD pioneer. The ratio is 12:1, CBD to THC, so the entourage effect happens synergistically making the cannabinoids work that much better together.

The ingredients are simple and only include: full spectrum organic cannabis oil, pharmaceutical grade MCT oil, organic non-GMO soy lecithin, and the vegan capsule is just cellulose and gellan gum. This is real medicine and great for relieving a variety of ailments. Perfect to relieve severe pain and anxiety, aids in the treatment of epilepsy, seizures, autism, is anti-inflammatory, helps with insomnia, stress disorders, depression, lupus, arthritis, glaucoma, nausea and so much more.

Independant review by Edibles Magazine

Many of these formulations were created from information gathered from Apollon’s proprietary artificial intelligence techniques and include:

  • Apollon NAUSEA™
  • Apollon PAIN™
  • Apollon SLEEP™
  • Apollon ANTI-INFLAMMATORY™
  • Apollon SEIZURES™
  • Apollon APPETITE™
  • Apollon CANCER™

Regulations

Apollon Licences

Apollon Formularies plc. indirectly holds a significant interest in Apollon Formularies Jamaica Limited (“Apollon Jamaica”).

Apollon Jamaica is Cannabis Licensed Authorities (CLA) licensed to operate on the Federal level in Jamaica.

  • Research and Development Licence (Experimental)
  • Retail Licence (Therapeutic)
  • Processing Licence
  • Cultivation (R&D)
  • Export (Based on the above licences)

Jamaican Regulatory Environment

The Cannabis Licensing Authority (CLA), an agency of the Ministry of Industry, Commerce, Agriculture and Fisheries, was established in 2015 under the Dangerous Drug (Amendment) Act, (DDA) with a specific role to establish and regulate Jamaica’s legal ganja and hemp industry.

  • Strengthening the capacity and programs of the NCDA
  • Strengthening Jamaica’s mental health institutions
  • Funding scientific and medical research into ganja and hemp
  • Supporting the regulatory arrangements of the CLA

Our Team

Our team consists of Board Members, Management Team, Advisory Board Members & Consultants

Board Members

Apollon Founder, Dr. Stephen Barnhill is a medical doctor with 35 years’ experience as Chairman and CEO of numerous publicly traded and private companies specialising in laboratory medicine, biotechnology, and pharmaceuticals. He was an early pioneer in the use of artificial intelligence (machine learning) techniques in medicine, primarily in the field of cancer diagnostics. Dr. Barnhill is an inventor on more than 40 international patents on artificial intelligence and his patents were part of the Intellectual Property portfolio that won MDB Capital’s MICO Award for most disruptive IP portfolio out of 1,600 publicly traded companies. Some of Dr. Barnhill’s early AI patents were acquired by Johnson and Johnson.

DR STEPHEN BARNHILL

Dr. Stephen Barnhill
MD

Chairman & CEO
Read More

Nick is a founding member of Apollon Formularies, Inc., a US corporation formed in 2014 to study and understand the benefits of medical cannabis to patients with varying medical conditions. In 2015, Nick was a key part of the team that oversaw the implementation of Apollon Formularies international expansion into Jamaica to lever off federal legislation allowing medical cannabis research and development for treating patients. Nick resided in Jamaica where he assisted in the roll out of Apollon Formularies Jamaica Ltd which has grown into a vertically integrated fully licensed medical cannabis company (licensed by the Cannabis Licensing Authority (CLA).

NICHOLAS F BARNHILL

Nicholas F Barnhill

Director
Read More

A capital markets veteran with over 30 years’ experience, Mr Sheil contributes a broad depth of experience and knowledge of capital markets to the board of Apollon. Kevin also brings key expertise to Apollon UK from working as a consultant to an Artificial Intelligence (“AI”) technology firm, providing valuable input as Apollon continues to grow its line of AI-determined patient specific cannabis medicines and commercialise its unique 3D Pharmaceutical Printer. Mr. Sheil began his career at the London Stock Exchange before moving into corporate broking with HSBC, Credit Lyonnais and Barclays. Mr. Sheil was a telecom sector specialist with Barclays, Credit Suisse and then Citibank where he worked for over 10 years and was consistently top ranked in Extel & Institutional Investor surveys. Mr Sheil worked as Head of Multi-Product Sales at Citibank and was responsible for broking all equity-based products. Mr Sheil has also spent over nine years as a general equity fund manager for Trium Capital Managers.

KEVIN SHEIL

Kevin Sheil

Director
Read More

Nick is an oil gas executive with over 19 years’ experience across a wide range of corporate roles in and around the oil gas industry including M&A, business development, financing, commercial, investor relations and operational functions Nicholas started his career in banking with roles at Morgan Stanley (energy investment banking) and RBS (structured energy lending debt advisory) before joining the oil gas industry working for AIM listed Valiant Petroleum plc, LSE listed Salamander Energy plc and AIM listed Faroe Petroleum Plc Nicholas is currently Business Development Director and member of the executive team at AIM listed Longboat Energy plc He has MA Hons degree from the University of St Andrews in Ancient History.

NICOLAS INGRASSIA

Nicolas Ingrassia

Director
Read More

Management Team

Dr. Stephen Barnhill is a medical doctor with 35 years’ experience as Chairman and CEO of numerous publicly traded and private companies specialising in laboratory medicine, biotechnology, and pharmaceuticals. He was an early pioneer in the use of artificial intelligence (machine learning) techniques in medicine, primarily in the field of cancer diagnostics. Dr. Barnhill is an inventor on more than 40 international patents on artificial intelligence and his patents were part of the Intellectual Property portfolio that won MDB Capital’s MICO Award for most disruptive IP portfolio out of 1,600 publicly traded companies. Some of Dr. Barnhill’s early AI patents were acquired by Johnson and Johnson.

DR STEPHEN BARNHILL

Dr. Stephen Barnhill
MD

CEO
Read More

Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, MD Anderson Cancer Center in Houston, Texas for 41 years. He has published over 200 peer-reviewed scientific papers, invited articles and book chapters. Dr Fritsche served as a consultant to the National Cancer Institute (NCI), the Expert Panel for developing Tumour Marker Practice Guidelines for the American Society of Clinical Oncology (ASCO) from its inception until his retirement from MD Anderson Cancer Center, the Laboratory Practice Guidelines Committee for the National Academy of Clinical Biochemistry, and the Editorial Board of six international scientific journals, He was awarded the Johnson & Johnson Award for Outstanding Research & Contributions to Clinical Biochemistry, the Abbott-ISOBM Award for Outstanding research in oncology the and the Morton K Schwartz Award for Outstanding Cancer Research.

DR HERB FRITSCHE

Dr. Herb Fritsche
PH.D

Chief Science Officer
Read More

With over fifteen years in the cannabis industry, Jeff has become a leading expert in volatile and nonvolatile extraction, method development, lab design, cultivation and the overall business of cannabis. Founder of RELM Labs , later evolving into W vapes. They built the company ,W vapes, to one of the biggest brands in the industry, in three states before their successful exit. He has also developed multiple medical cannabis products, including “Tommy’s Oil”, developed for Tommy Chong products via RELM, medicinal tinctures, capsules and vapes for Apollon Formularies Jamaica and has won 27 first place awards for his extracts and products, (Chalice Cup for best vape cartridge, 5 Hempcon awards including The Dab cup and Champions cup, 6 Local Sesh Awards for best oil, highest cbd oil, best new product and most potent thc oil, 6 awards for Edibles List magazine best of 2018, Abracadabs best oil and 2019 Jack Herer cup Jamaica for best solvent based extract). Since 2017, Jeff has worked alongside the Apollon team bringing his skill set to Dr. Barnhill's global brand as well as a team member of AI Pharmaceuticals in their cancer research studies.

Jeff Nagel

Jeff Nagel

Vice President and Director of Medical Product Development
Read More

Former General Secretary of the Jamaican People's National Party (PNP) from 2014-2016. Chairman and Founding Member of the National Alliance for the Legalization of Ganja. Project Manager, Founding Member of the Cannabis Commercial and Medicinal Task Force Programme. Director and Founding Member of the Ganja Growers and Producers Association of Jamaica. Chairman of the Jamaican Wellness and Health Network.

PAUL BURKE

Paul Burke

CEO Apollon Formularies Jamaica
Read More

Stephen was a Co-Founder and President of Apollon Formularies, Inc. in the US established in 2014. He was instrumental in the international expansion of Apollon Formularies to Jamaica in 2015 starting Apollon Formularies Jamaica, Ltd and obtaining a suite of vertical medical cannabis licenses from the Cannabis License Authority (CLA) including Cultivation Research and Development, Processing, and Retail Therapeutic allowing Apollon Formularies Jamaica to become a federally legal medical cannabis operation in Jamaica. Stephen was a Co-Founder and President of Doc’s Place international, a medical resort in Negril, Jamaica where international patients can stay while being treated by Apollon Formularies Jamaica’s team of Jamaican licensed medical doctors. He was involved in the expansion of Apollon to Europe and as COO of Apollon Formularies, Ltd in London, UK, he assisted in the transformation to a publicly traded company, Apollon Formularies, plc, trading on the Aquis Exchange in London. Stephen is also Founder and CEO of CBev Ventures, Inc., a medical cannabis beverage company offering the High Spirits brand of drinks.

STEPHEN D. BARNHILL Jr.

Stephen D. Barnhill Jr.

Chief Operating Officer Jamaican Operations
Read More

Stene joined Apollon in December 2020 as Head of Corporate Development. He started his career in the Navy where he qualified as a South African Navy Diver in 1992. After leaving the Navy he started a long career spanning 20 years in Real Estate and had the good fortune to acquire a wide range of expertise in Property Development, Real Estate Finance, Debt and Equity structuring and Corporate Finance. He brings substantial Director level operational experience in both the corporate and entrepreneurial sectors where he has a strong track record in assisting new ‘start-ups’ implement successful strategic growth plans across various sectors. His career included the delivery of multiple projects for Standard Bank premises, as an independent consultant for the Industrial and Commercial Bank of China – at the time a Forbes no.1 Company (2013)

STENE JACOBS

Stene Jacobs

Chief Operating Officer
Read More

Dr Dingle Spence is a licensed Jamaican physician specialising in Clinical Oncology, Radiation Therapy, and Palliative Care Medicine for the past 25 years. She continues to work in the public sector at the Hope Institute and Kingston Public Hospitals and is an Associate Lecturer at the University of the West Indies. Dr Spence is cofounder of the nonprofit organization the Jamaica Cancer Care and Research Institute (JACCRI) (https://www.jaccri.org/) and is on the Board of Directors of the International Association for Hospice and Palliative Medicine. She is also a consultant expert to the International Atomic Energy Agency (IAEA) and currently sits on two Lancet Commissions dedicated to improving cancer care and health care globally.

DR MARGARET DINGLE SPENCE

Dr. Dingle Spence
MB BS

Medical Director
Apollon International Cancer Center
Read More

A general medical practitioner involved in holistic practice, focusing on health and wellness and prevention of disease, providing general, primary medical care for all age groups...infant to elderly.

DR MARJORIE VASSELL

Dr. Marjorie Vassell
MD BS

Medical Director
General Practice and Wellness
Read More

Advisory Board & Consultants

Dr Hall is a Neurosurgeon, Board-Certified and Fellowship Trained in brain and spine surgery. He has been practicing medicine for over 25 years. He earned his Doctor of Medicine degree from McGill University Faculty of Medicine and one of the first five physicians Certified by the state of Florida to recommend medical cannabis. Dr Hall has pioneered, developed, and practiced minimally invasive and endoscopic surgical techniques for the brain and spine since 1993. He has performed research in spinal electrophysiology at the University of Miami as part of the Miami Project to Cure Paralysis. Dr Hall has faculty appointments at Nova Southeastern University College of Medicine and the Herbert Wertheim Florida International University College of Medicine. Dr Hall has also lectured and taught students from Barry University and the University of Alabama. He is the President-Elect of the Miami-Dade Chapter of the National Medical Association, and he is also a member of the Congress of Neurological Surgeons, American Association of Neurological Surgeons, and the Florida Neurosurgical Society. Dr. Hall is actively involved with outreach programs and performs charity medical care in several countries.

DR ANTHONY HALL

Dr. Anthony Hall
MD, MDCM, FACS, FAAN

Director of Medical Advisory Board
Read More

Dr. Fritsche is a world-renowned Clinical Chemist and former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, MD Anderson Cancer Center in Houston, Texas for 41 years. He has published over 200 peer-reviewed scientific papers, invited articles and book chapters. Dr Fritsche served as a consultant to the National Cancer Institute (NCI), the Expert Panel for developing Tumour Marker Practice Guidelines for the American Society of Clinical Oncology (ASCO) from its inception until his retirement from MD Anderson Cancer Center, the Laboratory Practice Guidelines Committee for the National Academy of Clinical Biochemistry, and the Editorial Board of six international scientific journals, He was awarded the Johnson & Johnson Award for Outstanding Research & Contributions to Clinical Biochemistry, the Abbott-ISOBM Award for Outstanding research in oncology the and the Morton K Schwartz Award for Outstanding Cancer Research.

DR HERB FRITSCHE

Dr. Herb Fritsche
PH.D

Director of Scientific Advisory Board
Read More

Dr Dawes is a General Surgeon with additional expertise in Bariatrics with a fellowship in Bariatrics and Minimally Invasive Surgery at the Santa Casa Hospital in Curitiba, Brazil. From 2012-2015 he worked at the Spanish Town Hospital as a Senior Registrar in General Surgery and was Senior Medical Officer at the Savanna-La-Mar Public General Hospital. Dr Dawes is a Fellow of the American College of Surgeons (FACS).

DR ALFRED DAWES

Dr. Alfred Dawes
MBBS DM FACS

General Surgeon
Read More

Contact

Apollon Negril Facility

West End, Negril

Apollon International
Formularies Cancer Center

Ruthven Road, Kingston

map